See more : Jungfraubahn Holding AG (0QNG.L) Income Statement Analysis – Financial Results
Complete financial analysis of GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GlaxoSmithKline Pharmaceuticals Limited, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
- Clearway Energy, Inc. (CWEN) Income Statement Analysis – Financial Results
- Fortitude Group, Inc. (FRTD) Income Statement Analysis – Financial Results
- Kodiak Gas Services, Inc. (KGS) Income Statement Analysis – Financial Results
- Golden Apple Oil & Gas Inc. (GAPJ) Income Statement Analysis – Financial Results
- KSB Limited (KSB.NS) Income Statement Analysis – Financial Results
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 34.54B | 32.52B | 32.78B | 31.99B | 32.24B | 31.28B | 28.71B | 29.08B | 27.64B | 26.38B | 25.55B | 26.54B | 23.78B | 21.51B | 19.08B | 16.93B | 16.08B | 15.82B | 15.19B | 14.10B |
Cost of Revenue | 14.20B | 12.85B | 14.50B | 13.95B | 13.98B | 14.45B | 13.28B | 14.82B | 13.33B | 12.26B | 12.29B | 11.57B | 9.19B | 7.88B | 7.02B | 6.56B | 6.37B | 6.31B | 6.39B | 6.04B |
Gross Profit | 20.34B | 19.67B | 18.28B | 18.04B | 18.27B | 16.84B | 15.44B | 14.27B | 14.30B | 14.13B | 13.25B | 14.97B | 14.59B | 13.63B | 12.06B | 10.38B | 9.72B | 9.51B | 8.80B | 8.06B |
Gross Profit Ratio | 58.89% | 60.49% | 55.78% | 56.40% | 56.66% | 53.82% | 53.76% | 49.05% | 51.75% | 53.55% | 51.88% | 56.41% | 61.35% | 63.36% | 63.19% | 61.27% | 60.41% | 60.08% | 57.92% | 57.19% |
Research & Development | 25.44M | 19.10M | 18.29M | 18.07M | 21.80M | 23.27M | 22.52M | 18.96M | 19.96M | 17.55M | 26.29M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 486.29M | 291.87M | 425.92M | 184.70M | 170.48M | 277.32M | 368.75M | 55.75M | 65.70M | 4.13B | 56.88M | 41.43M | 6.93B | 6.04B | 5.31B | 4.42B | 4.16B | 4.60B | 4.37B | 4.10B |
Selling & Marketing | 1.80B | 1.66B | 1.84B | 1.72B | 2.01B | 2.06B | 1.54B | 1.84B | 1.92B | 1.11B | 1.94B | 1.67B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 7.36B | 1.95B | 2.26B | 1.90B | 2.18B | 2.34B | 1.91B | 1.89B | 1.98B | 5.23B | 2.00B | 1.71B | 6.93B | 6.04B | 5.31B | 4.42B | 4.16B | 4.60B | 4.37B | 4.10B |
Other Expenses | -483.84M | 10.33B | 9.03B | 9.63B | 11.29B | 8.93B | 8.76B | 7.20M | 7.16M | 0.00 | 6.54M | 5.27B | -1.61B | -1.13B | -870.56M | -1.06B | -723.33M | -763.15M | -460.81M | -315.63M |
Operating Expenses | 7.38B | 12.28B | 11.30B | 11.53B | 13.48B | 11.27B | 10.67B | 10.34B | 9.66B | 9.67B | 8.06B | 6.98B | 5.32B | 4.91B | 4.44B | 3.37B | 3.44B | 3.84B | 3.91B | 3.78B |
Cost & Expenses | 20.94B | 25.13B | 25.79B | 25.48B | 27.45B | 25.72B | 23.95B | 25.16B | 22.99B | 21.92B | 20.35B | 18.55B | 14.51B | 12.79B | 11.47B | 9.92B | 9.81B | 10.16B | 10.30B | 9.82B |
Interest Income | 678.50M | 698.12M | 717.45M | 1.11B | 762.06M | 772.79M | 525.93M | 721.09M | 1.21B | 1.58B | 1.74B | 1.75B | 1.45B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 17.99M | 18.10M | 19.96M | 35.31M | 63.36M | 5.54M | 1.89M | 2.50M | 4.21M | 0.00 | 3.32M | 3.34M | 3.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 695.36M | 656.23M | 680.42M | 784.61M | 825.34M | 484.47M | 377.33M | 257.11M | 247.77M | 202.82M | 198.81M | 178.39M | 204.08M | 176.28M | 163.69M | 163.37M | 205.37M | 200.76M | 199.83M | 217.24M |
EBITDA | 8.87B | 9.03B | 8.49B | 5.36B | 3.92B | 7.31B | 5.78B | 5.38B | 6.03B | 5.09B | 7.31B | 8.52B | 9.55B | 8.89B | 7.78B | 7.17B | 6.44B | 5.86B | 5.08B | 4.50B |
EBITDA Ratio | 25.69% | 27.83% | 25.54% | 26.28% | 19.41% | 22.43% | 19.60% | 16.91% | 21.78% | 19.29% | 27.61% | 37.19% | 48.29% | 42.16% | 40.37% | 34.79% | 31.72% | 25.45% | 20.61% | 27.14% |
Operating Income | 13.60B | 8.39B | 7.69B | 7.61B | 5.43B | 6.53B | 5.25B | 3.93B | 4.64B | 4.89B | 5.20B | 7.99B | 9.27B | 8.72B | 7.61B | 7.01B | 6.28B | 5.66B | 4.88B | 4.28B |
Operating Income Ratio | 39.38% | 25.81% | 23.46% | 23.80% | 16.85% | 20.88% | 18.28% | 13.50% | 16.79% | 18.52% | 20.34% | 30.12% | 38.99% | 40.52% | 39.90% | 41.40% | 39.02% | 35.80% | 32.16% | 30.35% |
Total Other Income/Expenses | -5.44B | -4.03B | -3.79B | -5.02B | -1.74B | 295.59M | 634.72M | 1.19B | 1.17B | -2.83B | 1.92B | 373.08M | -3.23B | 0.00 | -18.50M | -71.50M | -68.00M | -68.00M | -77.78M | 0.00 |
Income Before Tax | 8.16B | 8.36B | 7.79B | 5.50B | 3.06B | 6.83B | 5.40B | 5.11B | 5.79B | 6.05B | 7.11B | 8.34B | 9.27B | 8.72B | 7.61B | 7.01B | 6.28B | 5.66B | 4.88B | 4.28B |
Income Before Tax Ratio | 23.63% | 25.72% | 23.77% | 17.21% | 9.48% | 21.82% | 18.80% | 17.58% | 20.97% | 22.91% | 27.85% | 31.43% | 38.99% | 40.52% | 39.90% | 41.40% | 39.02% | 35.80% | 32.16% | 30.35% |
Income Tax Expense | 2.26B | 2.29B | 3.98B | 1.92B | 2.13B | 2.37B | 1.89B | 1.74B | 2.03B | 2.23B | 2.30B | 2.72B | 3.05B | 2.93B | 2.61B | 2.38B | 2.18B | 1.99B | 1.77B | 1.57B |
Net Income | 5.90B | 6.11B | 3.81B | 3.58B | 932.05M | 4.45B | 3.51B | 3.37B | 3.77B | 3.81B | 4.82B | 5.62B | 4.29B | 5.61B | 5.08B | 5.91B | 5.48B | 5.51B | 5.07B | 3.38B |
Net Income Ratio | 17.08% | 18.78% | 11.62% | 11.20% | 2.89% | 14.24% | 12.21% | 11.58% | 13.64% | 14.45% | 18.85% | 21.17% | 18.02% | 26.06% | 26.62% | 34.91% | 34.05% | 34.83% | 33.40% | 23.95% |
EPS | 34.83 | 36.05 | 22.48 | 21.14 | 5.50 | 26.29 | 20.70 | 19.88 | 22.21 | 22.50 | 28.44 | 33.17 | 25.30 | 33.09 | 29.98 | 34.89 | 32.32 | 32.53 | 29.55 | 19.34 |
EPS Diluted | 34.83 | 36.05 | 22.48 | 21.14 | 5.50 | 26.29 | 20.70 | 19.88 | 22.21 | 22.50 | 28.44 | 33.17 | 25.30 | 33.09 | 29.98 | 34.89 | 32.32 | 32.53 | 29.55 | 19.34 |
Weighted Avg Shares Out | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 171.62M | 174.65M |
Weighted Avg Shares Out (Dil) | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 169.41M | 171.62M | 174.65M |
Source: https://incomestatements.info
Category: Stock Reports